- BioNTech SE BNTX presented data from its ongoing Phase 1/2 trial of its CAR-T cell therapy candidate, BNT211, in advanced solid tumors.
- The preliminary results demonstrated a favorable safety profile and antitumor activity in testicular cancer patients.
- BNT211 comprises an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac).
- The presentation included data from 16 patients who received CLDN6 CAR-T cells at dose levels 1 (1x107 CAR-T cells) and 2 (1x108 CAR-T cells) alone or combined with CARVac.
- All 16 patients showed robust CAR-T cell expansion 10-17 days after infusion with cell frequencies close to 109 total counts in dose level 2.
- Adverse events and dose-limiting toxicities were manageable; mild to moderate cytokine release syndromes and one transient occurrence of mild neurotoxicity was observed.
- 6 of 14 evaluable patients showed a partial response, and 5 patients had stable disease with shrinkage of target lesions.
- One patient showed no change from baseline, and two patients were progressing.
- All 4 testicular cancer patients in the higher dose level had disease control, and 3 of these patients showed objective responses.
- In addition, 1 testicular cancer patient showed partial response after infusion of the lowest CAR-T dose level combined with CARVac.
- 4 of 5 patients in the CARVac combination group showed a partial response.
- Price Action: BNTX shares are up 0.11% at $170.44 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
